VivoSeq
Infectious Disease

Gram-Negative Bacterial Infections

12

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Gram-Negative Bacterial Infections is an emerging landscape with 12 programs across 5 companies. The most active players are Prism Pharmaceuticals, Shionogi, Melinta Therapeutics, Inc.. 8 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

6/100

Mech. Concentration

60/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Prism Pharmaceuticals

1 program

ApprovedShionogi logo

Shionogi

1 program

ApprovedM

Melinta Therapeutics, Inc.

1 program

ApprovedPfizer logo

Pfizer

4 programs

ApprovedT

Triax

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Recruiting3 · 100%

Clinical Trials

Trial Activity

A Combination Therapy With Ceftazidime and Fosfomycin Will be Compared to Ceftazidime Alone in Hospitalized Adult Patients With Suspected Severe Gram-negative Bacterial Infections
Recruiting·AAngela HUTTNER·Phase 3·NCT07063095·100 enrolled
Optimising TREATment for Severe Gram-Negative Bacterial Infections
Recruiting·NNational University of Singapore·Phase 4·NCT07004049·600 enrolled
A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
Recruiting·Pfizer logoPfizer·Phase 2·NCT05639647·48 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)